XML 35 R28.htm IDEA: XBRL DOCUMENT
v3.25.3

Segments (Tables) | 9 Months Ended
--- | ---
Sep. 30, 2025
Segment Reporting [Abstract] |
Schedule of Reportable Segment Loss | The following table presents reportable segment loss, including significant expense categories, attributable to the Company’s reportable segment for the periods presented:
|  | Three Months Ended September 30, |  |  | Nine Months Ended September 30, |
|  | 2025 |  |  | 2024 |  |  | 2025 |  |  | 2024 |
Chronic cough in IPF clinical trial expense |  | $ | 822 |  |  | $ | 4,592 |  |  | $ | 6,743 |  |  | $ | 11,116 |
Refractory chronic cough clinical trial expense |  |  | 119 |  |  |  | 2,035 |  |  |  | 1,371 |  |  |  | 4,642 |
Clinical trial material |  |  | 4,304 |  |  |  | 713 |  |  |  | 5,622 |  |  |  | 3,875 |
Other clinical trials and studies 1 |  |  | 780 |  |  |  | 908 |  |  |  | 1,344 |  |  |  | 2,245 |
Other clinical development expenses 2 |  |  | 1,549 |  |  |  | 1,217 |  |  |  | 4,827 |  |  |  | 2,969 |
Employee compensation (excluding stock compensation expense) |  |  | 3,041 |  |  |  | 2,284 |  |  |  | 8,816 |  |  |  | 6,716 |
Stock-based compensation expense |  |  | 1,243 |  |  |  | 822 |  |  |  | 3,835 |  |  |  | 2,671 |
Other segment items 3 |  |  | 2,045 |  |  |  | 1,497 |  |  |  | 6,518 |  |  |  | 5,021 |
Interest income, net |  |  | (2,101 | ) |  |  | (826 | ) |  |  | (4,633 | ) |  |  | (2,759 | )
Net loss |  | $ | 11,802 |  |  | $ | 13,242 |  |  | $ | 34,443 |  |  | $ | 36,496 |
(1) Includes expense related to the Company’s drug-drug interaction study, human abuse potential study, Phase 2 CANAL trial of Haduvio for the treatment of chronic cough in patients with IPF, and Phase 2b/3 PRISM trial of Haduvio for the treatment of prurigo nodularis. (2) Includes expense related to general research and development activities, regulatory, medical affairs, and quality assurance. (3) Includes general administrative expense, interest expense, net, other (expense) income, net and income tax benefit.

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration